Free Trial

MacroGenics (MGNX) Stock Forecast & Price Target

MacroGenics logo
$3.24 +0.03 (+0.93%)
(As of 11/22/2024 ET)

MacroGenics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
8
Buy
3

Based on 11 Wall Street analysts who have issued ratings for MacroGenics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 8 have given a hold rating, 2 have given a buy rating, and 1 has given a strong buy rating for MGNX.

Consensus Price Target

$7.63
135.34% Upside
According to the 11 analysts' twelve-month price targets for MacroGenics, the average price target is $7.63. The highest price target for MGNX is $14.00, while the lowest price target for MGNX is $4.00. The average price target represents a forecasted upside of 135.34% from the current price of $3.24.
Get the Latest News and Ratings for MGNX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MacroGenics and its competitors.

Sign Up

MGNX Analyst Ratings Over Time

TypeCurrent Forecast
11/24/23 to 11/23/24
1 Month Ago
10/25/23 to 10/24/24
3 Months Ago
8/26/23 to 8/25/24
1 Year Ago
11/24/22 to 11/24/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
8 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$7.63$8.11$8.11$11.83
Forecasted Upside135.34% Upside125.31% Upside132.41% Upside57.78% Upside
Consensus Rating
Hold
Hold
Hold
Buy

MGNX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MGNX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MacroGenics Stock vs. The Competition

TypeMacroGenicsMedical CompaniesS&P 500
Consensus Rating Score
2.36
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside135.34% Upside26,878.84% Upside7.66% Upside
News Sentiment Rating
Positive News

See Recent MGNX News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/7/2024JMP Securities
2 of 5 stars
S. Tuerkcan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
11/6/2024HC Wainwright
2 of 5 stars
 Reiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.00+6.10%
9/16/2024Evercore ISI
2 of 5 stars
R. Department
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/15/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$16.00 ➝ $14.00+319.16%
8/7/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Darout
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetMarket Perform ➝ Market Perform$8.00 ➝ $5.00+44.51%
8/1/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Pohlman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
7/31/2024B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$18.00 ➝ $5.00-4.76%
7/31/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Schmidt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
7/29/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$14.00 ➝ $9.00+65.44%
5/10/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$29.00 ➝ $7.00-52.28%
5/10/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:31 PM ET.


MGNX Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for MacroGenics is $7.63, with a high forecast of $14.00 and a low forecast of $4.00.

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 8 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MGNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MGNX, but not buy additional shares or sell existing shares.

According to analysts, MacroGenics's stock has a predicted upside of 135.34% based on their 12-month stock forecasts.

Over the previous 90 days, MacroGenics's stock had 1 upgrade and 1 downgrade by analysts.

MacroGenics has been rated by research analysts at Evercore ISI, HC Wainwright, and JMP Securities in the past 90 days.

Analysts like MacroGenics less than other "medical" companies. The consensus rating for MacroGenics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MGNX compares to other companies.


This page (NASDAQ:MGNX) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners